MBX Biosciences (MBX) Cash from Investing Activities (2023 - 2026)

MBX Biosciences has disclosed Cash from Investing Activities across 4 years of filings, most recently posting -$97.1 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$97.1 million, down 3109.83% year-over-year; the trailing twelve-month figure through Mar 2026 was -$184.0 million (down 6.5% YoY), and the FY2025 annual result was -$83.7 million, up 47.88% from the prior year.
• Cash from Investing Activities came in at -$97.1 million for Q1 2026 at MBX Biosciences, up from -$130.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $26.0 million in Q2 2025 to a low of -$130.0 million in Q4 2025.
• The 4-year median for Cash from Investing Activities is -$18.4 million (2023), against an average of -$37.0 million.
• Across the five-year window, Cash from Investing Activities soared 429.31% in 2025 and sank 3109.83% in 2026, its largest moves.
• MBX Biosciences' Cash from Investing Activities stood at -$29.0 million in 2023, then sank by 132.59% to -$67.3 million in 2024, then slumped by 93.0% to -$130.0 million in 2025, then increased by 25.29% to -$97.1 million in 2026.
• The last three Cash from Investing Activities figures came in at -$97.1 million (Q1 2026), -$130.0 million (Q4 2025), and $17.1 million (Q3 2025), per Business Quant data.